NASDAQ:HROW Harrow Health (HROW) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free HROW Stock Alerts $13.25 +0.52 (+4.08%) (As of 02:39 PM ET) Add Compare Share Share Today's Range$12.70▼$13.3050-Day Range$9.30▼$12.7352-Week Range$7.60▼$28.25Volume433,523 shsAverage Volume445,398 shsMarket Capitalization$468.52 millionP/E RatioN/ADividend YieldN/APrice Target$32.47 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harrow Health alerts: Email Address Harrow Health MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside147.8% Upside$32.47 Price TargetShort InterestBearish15.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 17 Articles This WeekInsider TradingAcquiring Shares$592,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.39) to $0.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector463rd out of 939 stocksPharmaceutical Preparations Industry218th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingHarrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.47, Harrow Health has a forecasted upside of 147.8% from its current price of $13.10.Amount of Analyst CoverageHarrow Health has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.55% of the outstanding shares of Harrow Health have been sold short.Short Interest Ratio / Days to CoverHarrow Health has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow Health has recently increased by 0.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarrow Health does not currently pay a dividend.Dividend GrowthHarrow Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 3.9 News and Social Media Coverage News SentimentHarrow Health has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Harrow Health this week, compared to 2 articles on an average week.Search Interest8 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows2 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $592,600.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.60% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow Health are expected to grow in the coming year, from ($0.39) to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow Health is -17.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow Health is -17.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow Health has a P/B Ratio of 6.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Harrow Health Stock (NASDAQ:HROW)Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesMarch 26, 2024 | insidertrades.comMark L. Baum Acquires 9,000 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMarch 23, 2024 | insidertrades.comOpaleye Management Inc. Acquires 50,600 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 26, 2024 | americanbankingnews.comHarrow Health (NASDAQ:HROW) PT Lowered to $26.00March 25, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Harrow Health, Inc.'s Q1 2024 Earnings (NASDAQ:HROW)March 24, 2024 | americanbankingnews.comOpaleye Management Inc. Buys 50,600 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMarch 21, 2024 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comWhy Is Harrow (HROW) Stock Up 5% Today?March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 20, 2024 | msn.comHarrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5MMarch 19, 2024 | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023March 19, 2024 | finance.yahoo.comHarrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023March 19, 2024 | businesswire.comHarrow Announces Fourth Quarter and Year-End 2023 Financial ResultsMarch 18, 2024 | benzinga.comEarnings Preview: Harrow HealthMarch 13, 2024 | finance.yahoo.comHarrow (HROW) Fell on Lowering the GuidanceMarch 5, 2024 | finance.yahoo.comHarrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024February 29, 2024 | finance.yahoo.comHere’s How Harrow (HROW) Weighed on SRK Capital’s PerformanceFebruary 15, 2024 | businesswire.comHarrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical ProductsJanuary 11, 2024 | msn.comHarrow says dry eye drug Vevye now available in USJanuary 11, 2024 | finance.yahoo.comHarrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye DiseaseJanuary 3, 2024 | bizjournals.comHarrow Inc. partners with technology companies for dry eye prescription VevyeDecember 9, 2023 | markets.businessinsider.comHarrow Health’s Strong Sales Growth and Strategic Acquisitions Fuel Buy RatingNovember 29, 2023 | finance.yahoo.comHarrow Completes Transfer of the TRIESENCE® New Drug ApplicationNovember 24, 2023 | seekingalpha.comHROWM Harrow Health, Inc. NT CAL 27November 20, 2023 | finance.yahoo.comHarrow to Present at Two Investor Conferences in NovemberNovember 17, 2023 | benzinga.comHarrow Recent Insider ActivityNovember 14, 2023 | msn.comHarrow Health (NASDAQ:HROW) Plummets on Dismal Q3 PrintSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$32.47 High Stock Price Target$37.00 Low Stock Price Target$26.00 Potential Upside/Downside+155.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-18.75% Pretax Margin-18.21% Return on Equity-29.48% Return on Assets-5.37% Debt Debt-to-Equity Ratio2.60 Current Ratio2.83 Quick Ratio2.61 Sales & Book Value Annual Sales$130.19 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book6.33Miscellaneous Outstanding Shares35,360,000Free Float30,554,000Market Cap$450.13 million OptionableOptionable Beta0.45 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsAEON BiopharmaNASDAQ:AEONPepGenNASDAQ:PEPGTheravance BiopharmaNASDAQ:TBPHKindred BiosciencesNASDAQ:KINShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsMark L BaumBought 9,000 shares on 3/22/2024Total: $104,310.00 ($11.59/share)Opaleye Management Inc.Bought 50,600 shares on 3/20/2024Total: $488,290.00 ($9.65/share)Vanguard Group Inc.Bought 48,673 shares on 3/11/2024Ownership: 5.150%Goldman Sachs Group Inc.Bought 13,926 shares on 3/1/2024Ownership: 0.154%Price T Rowe Associates Inc. MDBought 1,523 shares on 2/16/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions Should I buy or sell Harrow Health stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow Health's stock price target for 2024? 2 Wall Street analysts have issued 1-year price objectives for Harrow Health's shares. Their HROW share price targets range from $26.00 to $37.00. On average, they predict the company's stock price to reach $32.47 in the next year. This suggests a possible upside of 147.8% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2024? Harrow Health's stock was trading at $11.20 at the start of the year. Since then, HROW stock has increased by 17.0% and is now trading at $13.10. View the best growth stocks for 2024 here. When is Harrow Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HROW earnings forecast. How were Harrow Health's earnings last quarter? Harrow Health, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.12. The company had revenue of $34.27 million for the quarter, compared to the consensus estimate of $37.58 million. Harrow Health had a negative trailing twelve-month return on equity of 29.48% and a negative net margin of 18.75%. Harrow Health's revenue for the quarter was up 50.1% compared to the same quarter last year. During the same period last year, the business earned ($0.06) EPS. What ETFs hold Harrow Health's stock? ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Harrow Health issued on next quarter's earnings? Harrow Health issued an update on its FY 2024 earnings guidance on Friday, March, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $188.7 million. What other stocks do shareholders of Harrow Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). Who are Harrow Health's major shareholders? Harrow Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (10.88%), Vanguard Group Inc. (5.15%), Vanguard Group Inc. (5.15%), Braidwell LP (4.27%), Ophir Asset Management Pty Ltd (1.56%) and Stifel Financial Corp (1.23%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow Health? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HROW) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.